28 results on '"Akamatsu, H."'
Search Results
2. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
3. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
4. 384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
5. 1271P A phase II study of high-flow nasal cannula as palliative care in advanced cancer patients
6. 155TiP Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
7. 1291P A phase II study of nivolumab rechallenge therapy in advanced NSCLC patients who responded to prior anti-PD-1/L1 inhibitors: West Japan Oncology Group 9616L
8. 1501TiP A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
9. 1236MO A single-arm phase II study of gefitinib with concurrent thoracic radiotherapy in unresectable locally-advanced non-small cell lung cancer patients with EGFR mutation (West Japan Oncology Group 6911L)
10. LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
11. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
12. 600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC).
13. EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)
14. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
15. An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
16. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy
17. 487P Establishment of novel multiplexed assay to detect EGFR mutations using ultra-sensitive digital PCR
18. 484PD A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer
19. 421P - EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC)
20. 1536TiP - An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
21. Plasma Epidermal Growth Factor Receptor Mutation Analyses in Japanese Advanced Non-Small-Cell Lung Cancer Patients Horboring Egfr Mutation By Rnase H-Dependent Pcr and Blocking Oligo Dependent Pcr Methods
22. Concurrent Genetic Alterations in Lung Cancer: a Comprehensive Genomic Profiling in a Japanese Cohort
23. Surrogate Markers of Survival in Locally Advanced Non-Small Cell Lung Cancer: Meta-Analysis from Randomized Trials
24. Disease Flare after Gefitinib Discontinuation
25. Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma
26. 1566P - Concurrent Genetic Alterations in Lung Cancer: a Comprehensive Genomic Profiling in a Japanese Cohort
27. 244P - Plasma Epidermal Growth Factor Receptor Mutation Analyses in Japanese Advanced Non-Small-Cell Lung Cancer Patients Horboring Egfr Mutation By Rnase H-Dependent Pcr and Blocking Oligo Dependent Pcr Methods
28. O3–099SURROGATE MARKERS OF SURVIVAL IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: META-ANALYSIS FROM RANDOMIZED TRIALS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.